In the paper by Szaflarski et al 1 the authors highlighted the epidemiological relevance of this topic and describe the therapeutic options in detail.
The treatment indicated for TBI may involve multiple medications and/or surgical procedures. However, none of these treatments has as its purpose to prevent the occurrence of late posttraumatic epilepsy. Antiepileptic drugs currently in clinical use are indicated for the control of seizures that may occur but not to prevent progression to epilepsy. A strong point of the paper refers to future directions in the treatment, including new insights into epileptogenesis. However, despite widespread discussion of treatments in this paper some considerations were not included. An important consideration should be the mechanisms involved in the genesis of posttraumatic epilepsy, including some evidence of a genetic component and posttraumatic epilepsy, 3 important information about inflammatory mechanisms and blood-brain barrier dysfunction associated with this posttraumatic disorder, 4 and their impacts in future directions of the treatment. It should also be considered that a number of compounds successfully tested at the preclinical level, despite lacking clinical relevance, might bring insights in terms of mechanisms of action for antiepileptogenesis or disease modification. 5 Finally the authors failed to mention strong preclinical evidence indicating that neuroprotection, per se, does not influence antiepileptogenesis nor provide disease modification of posttraumatic epilepsies. 6 These small caveats, however, do not take away the main relevant messages and discussion raised by Szaflarski et al.
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